Translational Research InstituteTRI will bring four of the country's pinnacle research facilities together with the aim of translating the findings of basic biomedical research into better patient outcomes. The Institute will allow - for the first time in Australia - biopharmaceuticals and treatments to be discovered, produced, clinically tested and manufactured in one location. The Institute is the outcome of the collective vision of 2006 Australian of the Year Professor Ian Frazer and Professor Derek Hart, former Director of Mater Medical Research Institute, together with clinicians and scientists from the Diamantina Health Partners, an integrated health sciences centre. |
The Institute is a joint venture between The University of Queensland Diamantina Institute, Queensland University of Technology’s Institute of Health and Biomedical Innovation, Mater Medical Research Institute and the Princess Alexandra Hospital’s Centres for Health Research and has been made possible through $354 million in funding provided by the Australian and Queensland Governments, The Atlantic Philanthropies, UQ and QUT.
Research focusTRI will focus on better prevention and treatment of specific health problems including cancer, infection, arthritis, autoimmunity, diabetes, and trauma.
|
||
Employment Opportunities at TRI Click here to see what positions
|
Latest NewsClick here to view the news and events. |